

SPECTRUM PHARMACEUTICALS INC  
Form 8-K  
May 21, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**  
**Securities Exchange Act of 1934**

**Date of report (Date of earliest event reported): May 20, 2013**

**SPECTRUM PHARMACEUTICALS, INC.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35006**  
(Commission  
File Number)

**93-0979187**  
(IRS Employer  
Identification No.)

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form 8-K

11500 S. Eastern Ave., Ste. 240, Henderson, NV  
(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (702) 835-6300

89052  
(Zip Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

On May 20, 2013, at the UBS Global Healthcare Conference in New York City, after highlighting the safe harbor disclosures pertaining to forward looking statements, Rajesh C. Shrotriya, MD, Chairman of the Board, Chief Executive Officer and President of Spectrum Pharmaceuticals, Inc. (the Company), in response to a question about revenue guidance for Fusilev and the Company, confirmed prior Company expectations that Fusilev annual sales are anticipated to be approximately \$80 to \$90 million and total Company revenue is anticipated to be approximately \$160 to \$180 million for the 2013 fiscal year. As with all forward looking statements, there can be no assurance that such results will be achieved.

*Forward-looking statement* This Form 8-K contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including sales of Spectrum's drug products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include our lack of sustained revenue history, our limited marketing experience, our customer concentration, the possibility customer buying patterns may change, evolving market dynamics, our dependence on third parties for clinical trials, manufacturing, distribution and quality control, risks related to drug development and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this Form 8-K except as required by law.

*The information in this Current Report on Form 8-K is furnished pursuant to Item 7.01 and shall not be deemed filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.*

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Spectrum Pharmaceuticals, Inc.**

Date: May 20, 2013

By: /s/ BRETT L. SCOTT

Name: Brett L. Scott

Title: Senior Vice President and Acting Chief Financial Officer